Announcement • May 19
Turn Therapeutics Inc. Appoints Stephen M. Hahn as Executive Clinical and Regulatory Lead Turn Therapeutics Inc. announced the appointment of Stephen M. Hahn, M.D., former Commissioner of the U.S. Food and Drug Administration (FDA), to oversee the clinical and regulatory strategy for GX-03, the Company’s investigational topical therapy currently in a Phase 2 clinical trial for moderate-to-severe atopic dermatitis (eczema). Stephen M. Hahn, M.D., is a physician, biotechnology executive, and former Commissioner of the U.S. Food and Drug Administration with decades of leadership experience spanning clinical medicine, regulatory science, healthcare operations, and medical product development. As the 24th FDA Commissioner from 2019 to 2021, Dr. Hahn oversaw both COVID and non-COVID regulatory activities, including therapeutics, vaccines, diagnostics, medical devices, and clinical trials. Prior to joining the FDA, Dr. Hahn served as Chief Medical Executive, Deputy President, and Chief Operating Officer at MD Anderson Cancer Center, where he helped oversee one of the world’s leading academic medical centers with more than 21,000 employees and a $5.2 billion operating budget. He also held senior academic and clinical leadership positions at MD Anderson and the University of Pennsylvania’s Perelman School of Medicine. In the biotechnology sector, Dr. Hahn has served in executive leadership roles including CEO-Partner at Flagship Pioneering and Chief Executive Officer of Harbinger Health. He has extensive experience in clinical research and medical product development, including topical therapies, and has authored more than 220 peer-reviewed scientific publications. Dr. Hahn earned his M.D. from Temple University and his B.A. in Biology from Rice University. He completed his internal medicine residency at University of California, San Francisco, and his fellowship and residency training at the National Cancer Institute in Bethesda, Maryland. Announcement • Mar 25
Turn Therapeutics Inc. announced that it expects to receive $25 million in funding from Avenue Capital Management II, L.P. Turn Therapeutics Inc. announced that it will raise $25 million in a round of funding on March 24, 2026. The transaction include participation from new investor Avenue Venture Opportunities Fund II, L.P., a fund managed by Avenue Capital Management II, L.P. The company has issued growth capital loan facility in the transaction.
On same date the company has received its first tranche of $7 million. Announcement • Jan 08
Turn Therapeutics Inc. Appoints Martin Dewhurst to Board of Directors On January 7, 2026, the board of directors (the “Board”) of Turn Therapeutics Inc. (the “Company”) enlarged the Board from five to six members and appointed Martin Dewhurst to the Board, effective immediately. Mr. Dewhurst will serve as an independent Class III director until his term of office expires at the annual meeting of the Company’s stockholders in 2028, or until his earlier death, resignation or removal. Mr. Dewhurst will serve as the chair of the compensation committee of the Board. Martin Dewhurst, age 62, has served as advisor to GHO Capital, a healthcare specialist private equity firm since July 2024. Mr. Dewhurst has been a senior advisor since April 2023 to PJT Partners, a global investment and M&A advisory bank. Mr. Dewhurst has also served as a senior advisor to LightRock, a growth capital fund, since April 2023. Mr. Dewhurst also holds various board positions including at Unilabs Ltd. (since September 2025), KOS AI (since June 2025), Cytovation ASA (since February 2025), Distalmotion (since April 2023) and MedGenome (April 2023 through January 2025). Prior to his various advisory and board roles, Mr. Dewhurst was a senior partner with McKinsey & Co., a leading management consulting firm where he served from 1992 through 2023 and co-led the firm’s life sciences practice (2014 to 2021). Mr. Dewhurst earned his undergraduate degree from Magdalen College, University of Oxford, and holds an MBA from INSEAD, where he graduated on the Dean’s List. Mr. Dewhurst’s more than 30 years of global leadership experience in life sciences, with a strong focus on mergers and acquisitions, complemented by senior advisory roles and board positions across leading healthcare and investment firms, make him well qualified to serve as a director. 
